AVSOLA (infliximab-axxq) for injection, for intravenous use. Initial U.S. Approval: 2019

Category: .

AVSOLA (infliximab-axxq) for injection, for intravenous use. Initial U.S. Approval: 2019

INDICATIONS AND USAGE
AVSOLA is a tumor necrosis factor (TNF) blocker indicated for:
Crohn’s Disease
Pediatric Crohn’s Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Rheumatoid Arthritis in combination with methotrexate
Ankylosing Spondylitis
Psoriatic Arthritis
DOSAGE FORMS & STRENGTHS
For injection: 100 mg of lyophilized infliximab-axxq in a 20 mL single-dose vial for intravenous infusion.
Manufactured By: Amgen Medical Information
Prescribing Information URL: Click Here

Access to AVSOLA (infliximab-axxq) for injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Infliximab was approved for medical use in the United States in 1998, and in the European Union in August 1999. Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.